throbber

`
`LUPIN EX 1058
`
`Page 1 of 17
`
`

`

`EDITION
`
`Remington
`Practice of
`
`ALFONSO R GENNARO
`
`Chairman of the Editorial Board
`and Editor
`
`
`
`
`Page 2 of 17
`
`
`

`

`
`
`dna91Cn.mCS.eh_.|
`yCa,m\raInD..
`
`1995
`
`MACK PUBLISHING COMPANY
`
`Easton, Pennsylvania 18042
`
`Page 3 of 17
`
`

`

`
`
`elivery for C
`d C
`S hemoth
`ratheCal d
`990.
`
`983.
`
`APTER 89
`
`,,
`o
`0
`mhalmic Preparations
`
`
`
`’ Implantab
`‘
`:5S3132? for
`ble Reserve
`
`hid Hecht, PhD
`r
`ired°rv Pharmaceutical Sciences
`bor0r3ri‘seiso1
`
`
`phthalmic preparations are sterile products essentially
`
`e from foreign particles, suitably compounded and pack-
`
`d for instillation into the eye. Ophthalmic preparations
`
`hide Solutions, suspensions, ointments and solid dosage
`
`rmS- The solutions and suspensions are, for the most part,
`ueous. Ophthalmic ointments usually contain a white pet-
`
`mum-mineral oil base.
`
`ophthalmic preparations can be grouped broadly into two
`
`isions of major significance to the pharmacist. These in-
`de single or multidose prescription products and the cat-
`
`Ory described as OTC or over-the-counter ophthalmic
`
`ducts. The latter group has been subjected to a searching
`
`'ew and analysis by a body of experts as a part of the FDA’s
`
`C Drug Review process.
`_
`
`The single dominant factor characteristic of all ophthalmic
`
`ducts is the specification of sterility. Any product in-
`
`ded for use in thereye regardless of form, substance or
`
`ent must be sterile. This requirement increases the simi—
`
`arity between ophthalmic and parenteral products, however
`
`he physiology of the human eye in many respects imposes
`
`re rigid formulation requirements. This will be consid—
`
`ered in the following discussion.
`,
`Preparationsintended for the treatment of eye disorders
`
`‘anbe traced to antiquity. Egyptian papyri writings describe
`
`eye medications. The Greeks and Romans expanded such
`
`rises and gave us the term collym'a. Collyria refer collec-
`
`tively to materials which were dissolved in water, milk or egg
`
`
`
`tifullady.” ,
`‘ From the time of belladonna Collyria, ophthalmic technol-
`
`Ogy progressed at a pharmaceutical snail’s pace'well into
`
`_
`It was not until after the second World war
`that the concept of sterility became mandatory for ophthalmic
`solutions. Prior to World War II and continuing into the
`
`
`
`
`. Preparations to be used in the eye, either solutions or oint—
`
`ments,
`invariably were compounded in the community or
`
`h_08pital pharmacy and were intended for immediate (prescrip-
`
`tlon) use. Such preparation and prompt use is reflected in
`
`the pharmaceutical literaturerof the'times. The stability of
`
`0Dhthalmic preparations is discussed in terms of days or a few
`months.
`,

`,
`,
`,
`
`‘ One of the most important attributes of ophthalmic prod-
`
`“Cts is the requirement of sterility. Even that, however, is a
`
`SuI‘prisingly recent event. The USP XV in 1955 was the'first
`Official compendium to include a sterility requirement for
`0_Dhthalmic solutions. The FDA in 1958 adopted the posi-
`t10n that a nonsterile ophthalmic solution was adulterated.
`Sterile ophthalmic products were, of course, available prior to
`the mid 19505, however the legal requirement of sterility
`dates only from 1955.
`.
`‘ The sterility requirements for ophthalmic ointments ap-
`- D‘3_ared first in the USP XVIII, Third Supplement (1972).
`Prlor to that date there was no legal requirement for a sterile
`
`
`
`ophthalmic ointment. This probably was due to the difficulty
`(at that time) of testing for sterility in such nonaqueous sys-
`tems and also for the anticipated difficulties in sterilizing and
`maintaining sterile conditions during the manufacture and
`filling of ointments on a large scale.
`
`Anatomy and Physiology of the Eye
`
`The human eye is a challenging subject for topical adminis-
`tration of drugs. The basis of this can be found in the anatomi-
`cal arrangement of the surface tissues and in the permeability
`of the cornea. The protective operation of the eyelids and
`lacrimal system is such that there is rapid removal of material
`instilled into the eye, unless the material is suitably small in
`volume and chemically and physiolOgically compatible with
`surface tissues. Figures 11 and 21 include pertinent anatomy
`of the human eye.
`Eyelids—«The eyelids serve two purposes: mechanical
`protection of the globe and creation of an optimum milieu for
`the cornea. The eyelids are lubricated and kept fluid-filled by
`secretions of the lacrimal glands and specialized cells residing
`in the bul'bar conjunctiva. The antechamber has the shape of
`a narrow cleft directly over the front of the eyeball, with
`pocket-like extensions upward and downward. The pockets
`are called the superior and inferior fornices (vaults), and the
`entire space, the cul-de-sac. The elliptical opening between
`the eyelids is called the palpebral fisSure.
`.-
`Eyeball—The wall of the human eyeball (bulbus, globe) is
`composed of three concentric layers.
`1. The outer fibrous layer.
`2. A middle vascular layer—-the uvea or uveal tract, consisting of the
`choroid, the ciliary body and the iris.
`3. A nervous layer—the retina.
`
`The outer layer is tough, pliable but only slightly stretchable.
`In its front portion—«the portion facing the outside world——
`the fine structure of the outer layer is so regular and the water
`content so carefully adjusted that it acts as a clear transparent
`window (the cornea).
`It is devoid of blood vessels. Over
`the remaining two-thirds the fibrous coat is opaque (the
`“white” of the eye) and is called the sclera.
`It contains the
`microcirculation which nourishes the tissues of this anterior
`segment and is usually white except when irritated and vessel
`dilatation occurs.
`The eyeball houses an optical apparatus that causes in-
`verted reduced images of the outside world to form on the
`retina, which is a thin translucent membrane. The optical
`apparatus consists, in sequence, of the precorneal film, the
`cornea, the aqueous humor, the pupil, the crystalline lens, the
`Vitreous humor and the retina. The aqueous and vitreous
`humors are layers of clear fluid or gel—like material interposed
`between the solid structures. The pupil, a round centric hole
`in a contractile membranous partition (called the iris), acts as
`the variable aperture of the system. The crystalline lens is a
`refractive element with variable power controlled and sup-
`ported by a muscle incorporated in the ciliary body. The
`choroid is the metabolic support for the retina.
`The optical function of the eye calls for stability of its
`dimensions, which is provided partly by the fibrous outer coat;
`
`1563
`
`Page 4 of 17
`
`

`

`
`
`
`
`
`encountered during this passage and the rate of aque
`production are the principal factors determining the 19Ve1 ,
`the intraocular pressure.
`In addition to this hydromech 0
`cal function, the aqueous humor acts as a carrier of “Utrientg
`
`substrates and metabolites for the avascular tissues of the eye
`
`The bones of the skull join to form an approximately Wm
`mid-shaped housing for the eyeball, called the orbit.
`Conjunctiva—The conjunctival membrane covers th
`
`outer surface of the white portion of the eye and the inne
`
`In most places it is attached 100se‘
`aspect of the eyelids.
`
`and thereby permits free movement of the eyeball.
`Thi
`makes possible subconjunctival injections. Except for th:
`cornea the conjunctiva is the most exposed portion of the eye
`
`Lacrimal System—The conjunctival and corneal surface
`are covered and lubricated by a film of fluid secreted by th
`
`conjunctival and lacrimal glands. The secretion of the lacr'
`mal gland, the tears, is delivered through a number of fin
`ducts into the conjunctival fornix. The secretion is a Clear
`
`watery fluid containing numerous salts, glucose, other organi
`compounds, approximately 0.7% protein and the enzyme
`
`lysozyme. Small accessory lacrimal glands are situated '
`the conjunctival fornices. Their secretion suffices for lubriCa
`tion and cleansing under ordinary conditions and for maintain
`
`ing a thin fluid film covering the cornea and conjunctiva (th
`precorneal film). The mucin-protein layer of the film is espe
`
`cially important in maintaining the stability of the film. Th
`main lacrimal gland is called into play only on Specia
`
`occasions. The sebaceous glands of the eyelids secrete a
`oily fluid which helps to prevent overflowing of tears at the li
`margin and reduces evaporation from the exposed surfaces 0
`
`the eye by spreading over the tear film.
`Spontaneous blinking replenishes the fluid film by pushing
`
`thin layer of fluid ahead of the lid margins as they com
`
`together. The excess fluid is directed into the lacrimali
`
`lake—a small triangular area lying in the angle bound by th
`innermost portions of the lids. The skin of the eyelids is th
`thinnest in the body and folds easily, thus permitting rapi
`opening and closing of the palpebral fissures. The move
`ment of the eyelids includes a narrowing of the palpebra
`,
`fissures in a zipper-like action from the lateral canthus towar
`the medial cant-hus (canthi:
`the corners where the eyelids.
`meet). This aids the transport or movement of fluid toward '
`the lacrimal lake.
`.
`Tears are drained from the lacrimal lake by two small
`tubes—the lacrimal canaliculi—which lead into the upper
`part of the nasolacrimal duct, the roomy beginning of which is
`called the lacrimal sac. The drainage of tears into the nose
`does not depend merely on gravity. Fluid enters and passes
`along the lacrimal canaliculi by capillary attraction aided by
`aspiration caused by contraction of muscle embedded in the
`eyelids. When the lids close, as in blinking, contraction of
`the muscle causes dilatation of the upper part of the lacrimal
`sac and compression of its lower portion. Tears are thus
`aspirated into the sac, and any which have collected in its
`lower part are forced down the nasolacrimal duct toward its
`opening into the nose. As the lids open, the muscle relaxes.
`The upper part of the sac then collapses and forces fluid into
`the lower part, which at the same time is released from
`compression. Thus, the act of blinking exerts a suction-force-
`pump action in removing tears from the lacrimal lake and
`emptying them into the nasal cavity. Lacrimation is induced
`reflexly by stimulation of nerve endings of the cornea 01”
`conjunctiva. The reflex is abolished by anesthetization of the
`surface of the eye and by disorders affecting its nerve compo—
`nents.
`
`The normal cul-de-sac usually is free of pathogenic organ-
`isms and often found sterile. The sterility may be due partly
`to the action of lysozyme in the tears, which normally destroys
`saprophytic organisms but has little action against pathogens.
`More effective in producing sterility may be the fact that the
`secretions, which are normally sterile as they leave the glands,
`constantly wash the bacteria, dust, etc, down in the nose.
`In
`certain diseases the lacrimal gland, like other glandular struc-
`tures in the body, undergoes involution, with the result that
`
`
`
`1564
`
`CHAPTER 89
`
`EXCRETORY DUCT
`
`
`
`
`CONJUNCTIVA——‘
`‘ CONJUNCTIVAL
`[31
`
` SAC——-——‘-— ,
`
`WOLFRING‘S
`(
`GLANDS-—‘—-—-—————-
`GLANDS OF
`
`
`
`
`E
`
`MANZ
`
` \
`
`CRYPTS OF
`HENLE
`
`MEIBOMIAN
`GLANDS
`
`TARSAL PLATE
`
`
`
`VITREOUS
`HUMOR
`
`
`TGLANDS OF
`ZEIS
`
`(SEBACEOUS)
`'
`
`
`
`
`
`GLANDS OF MOLL/
`
`(SWEAT)
`
`Fig 1.
`
`The eye:
`
`vertical section.1
`
`more effective as a stabilizing factor is the intraocular pres-
`sure, which is in excess of the pressure prevailing in the
`surrounding tissues. This intraocular pressure is the result
`of a steady production of specific fluid, the aqueous humor,
`which originates from the ciliary processes and leaves the eye
`by an intricate system of outflow channels. The resistance
`
`
`
`
`LACRIMAL GLAND
`
`
`
`EXCRETOR’r DUCTS
`
`NASAL
`SEPTUM
`
`
`
`
`INFERIOR CONCHA
`
`‘
`
`.
`
`"VALVE" OF HASNER/VII
`(LACRIMAL PLICA)
`
`Fig 2. Nasolacrimal duct.1
`
`
`
`Page 5 of 17
`
`

`

`
`
`
` 1acrimal fluid becomes scanty. Furthermore, changes in
`COnjunctival glands may lead to alteration in the character
`he secretion so that quality as well as quantity of tearsmay
`
`abnormal. This may lead to symptoms of dryness, burn-
`, and general discomfort, and may. interfere with visual
`
`I.Z'corneal Film—The cornea must be wet to be an opti-
`1y adequate surface; when dry, it loses both its regular gloss
`
`its transparency. The precorneal film, part of the tear
`Ched 100
`d provides this important moist surface.
`Its character
`
`yeball,
`ends on the condition of the corneal epithelium. The
`
`(cept f0
`COmpatible with both aqueous and lipid ophthalmic prepa-
`
`on of thee
`«Ens. is composed of a thin outer lipid layer, a thicker
`
`neal Sulfa
`ddle aqueous layer and a thin inner mucoid layer.
`It is
`
`ewed during each blink and when blinking issuppressed,
`
`her by drugs or by mechanical means, it dries, in patches.
`
`gems to be unaffected by the addition of concentrations of
`
`to 2% sodium chloride to conjunctival fluid. A pH below 4
`above 9 causes derangement of the film. The film affects
`
`he movement of contact lenses and forms more easily on
`
`" 2155 than on plastic prostheses.
`-
`Cornea—The cornea, from 0.5 to 1 mm thick, consists
`
`inly of the following structures (from the front backwards):
`
`, Corneal epithelium.
`
`_ .2. Substantia propria (stroma).
`
`, 3. Corneal endothelium.
`
`s secrete
`he cornea is transparent to ordinary diffuse light, largely
`
`ars at the
`ecause Of a special laminar arrangement of the cells and
`
`hers and because of the absence of blood vessels.
`:1 surfaces
`
`Gioudiness of the cornea may be due to any one of several
`
`actors including excess pressure in the eyeball as in glau-
`by pushin
`
`‘oma; scar tissue due to injury, infection or deficiency of
`‘xygen or excess hydration such as may Occur during the
`
`ound byt
`wearing of improperly fitted contact lenses. A wound of the
`
`yelids ist
`ornea usually. heals as an opaque patch which can be a
`
`utting rap
`ermanent impairment of vision unless it is located in the
`
`‘eriphery of the cornea.
`_,-
`,
`
`; The chief refraction of lightfor the eye occurs at the outer
`
`urface of the cornea where the index of refraction changes
`
`rom that of air (1.00) to that of precorneal substance (1.38).
`
`Any alteration in its shape or transparency interferes with the
`
`ormation of a clear image; therefore, any pathological pro-
`
`two sm ,
`ess, however slight, may interfere seriously with the resolv-
`
`t the upper.
`ng power or.visual acuity of the eye.
`.
`
`g of which _
`The normal cornea possesses no blood vessels except at the
`
`to the nose?
`orneoscleral junction. The cornea, therefore, must derive
`
`and passes
`ts nutrition by diffusion and must have certain permeability
`
`)n aided b .
`,_ characteristics; it also receives nourishmentfrom the fluid
`dded in the
`:_ Circulating through the chambers of the eye and from the air.
`
`The fact that the normal cornea is devoid of blood vessels is an
`itraction of:
`
`iInportant feature in surgical grafting. The corneal nerves do
`he lacrimal
`not supply all forms of sensation to the cornea. Pain and
`rs are thus
`acted in its ‘
`Cold are well supplied. The pain fibers have avery low thresh—
`
`; toward its
`01d, which makes the cornea one of the most sensitive areas on
`
`:le relaxes.
`the surface of the body.
`It now is agreed generally that the
`
`as fluid into
`- cornea possesses a true sense of touch; nerve endings supply-
`
`eased from
`111g the sensation of heat are lacking.
`,
`
`:tion-force-
`The corneal epithelium provides an efficient barrier against
`
`ll lake and
`* bacterial invasion. Unless its continuity has been .broken by
`is induced
`an abrasion (a traumatic opening or defect in the epithelium)
`
`cornea 01”
`pathogenic bacteria, as a rule, cannot gain. a foothold.
`
`ation of the
`Trauma, therefore, plays an important part in mostof the
`
`ve compo-
`1 Infectious diseases of the cornea which occur exogenously.
`
`Any foreign body that either scratches the cornea or lodges
`
`enic organ-
`and becomes imbedded in the cornea is of serious moment
`due partly
`because of the role it may play in permitting pathogenic
`ly destroyS
`bacteria to gain a foothold.
`.
`.
`,
`)athogenS-
`A means of detecting abrasions on the corneal surface is _
`ct that the
`afforded by staining the cornea with sodium fluorescein.
`If
`:he glands.
`there is an abrasion 0n the epithelium, the underlying layer
`. nose.
`In
`stains a brilliant green, so that even pinpoint abrasions show
`ular struC'
`up quite clearly. Abrasion may occur during tonometry, that
`result that
`is, during the measurement of ocular tension (pressure) with a
`
`
`
`OPHTHALMIC PREPARATIONS
`
`1565
`
`tonometer.
`Care must be used in applying the device to the
`Corneal abrasions
`cornea to avoid abrasion .of the cornea.
`Every cor-
`sometimes result from wearing contact lenses.
`neal abrasion is subject to infection.
`
`Bioavailabiilvity
`
`. ‘Physical Consideration—Under normal conditions the
`human tear volume averages about 7 uL.2 The estimated
`maximum volume of the cul-de-sac is about 30 uL with drain-
`age capacity far exceeding lacrimation rate. The outflow
`capacity accommodates the sudden large volume resulting
`from the instillation of an eyedrop. Most commercial eye—
`drops range from 50 to 75 uL in volume, however, much in
`excess of 50 'p.L probably is unable to enter the cul-de-sac.
`Within the rabbit cul-de—sac, the drainage rate has been
`shown to be proportional to the instilled drop volume.
`Multiple drops administered at intervals produced higher drug
`concentrations.
`Ideally, a high concentration of drug in a
`minimum drop volume is desirable. Patton3 has shown that
`approximately equal tear-film concentrations result from the
`instillation of 5 uL of 1:61 x 10‘2 M pilocarpine nitrateor
`from 25 p.L of 1.0 X 10‘2M solution. The 5 uL contains only
`38% as much pilocarpine, yet its bioavailability is greater due
`to decreased drainage loss.
`.
`There is a practical limit or limits to the concept of mini-
`mum dosage volume. There is a difficulty in designing and
`producing a dropper configuration which will deliver small
`volumes reproducibly. Also, the patient often cannot detect
`the administration of such a small volume. This sensation or
`lack of' sensation is particularly apparent at the 5.0—7.5-uL
`dose-volume range.
`‘
`The concept of dosage-volume drainage and cul—de-sac ca-
`pacity directly effects the prescribing and administering of
`separate ophthalmic preparations. The first drug adminis-
`tered may be diluted significantly by the administration of the
`second. On this basis combination drug products for use in
`
`ophthalmology have considerable merit.
`.
`Corneal Absorption
`Drugs administered by instilla-
`tion must penetrate the eye and do so primarily through the
`cornea. Corneal absorption is much more effective than
`scleral or conjunctival absorption where removal by blood
`vessels into the general circulation occurs.
`Many ophthalmic drugs are weak bases and are applied to
`the eye as aqueous solutions of their salts. The free base and
`the salt will be in an equilibrium which will depend on the pH
`and on the individual characteristics of the drug molecule.
`To aid in maintaining storage stability and solubility, the medi-
`cation may be acidic at the moment of instillation but, usually,
`the, neutralizing action of the lacrimal fluid will convert it
`rapidlyto the physiological pH range (approximately pH 7.4),
`at which there will be enough free base present to begin
`penetration of the corneal epithelium. Once inside the epi-
`thelium the undissociated free base dissociates immediately
`to a degree. The dissociated moiety then will tend to pen-
`etrate the stroma because it is water-soluble. At the junction
`of the stroma and endothelium the same process that took
`place at the outer surface of the epithelium must occur again.
`Finally, the dissociated drug leaves the endothelium for the
`aqueous humor. Here it can readily diffuse to the iris and the
`ciliary body, the site of its pharmacological action.
`The cornea can be penetrated by ions to a small, but measur-
`able, degree. Under comparable conditions, the permeabili-
`ties are similar for all ions of small molecular weight, which
`suggests that thepassage is through extracellular spaces.
`The diameter of the largest particles which can ass across the
`cellular layers seems to be in the range 10—25
`. An instilled
`drug is subject to protein binding in the tear fluid and meta-
`bolic degradation by enzymes such as lysozyme, in addition to
`the losses by simple overflow and lacrimal drainage.
`’ Since the cornea is a membrane including both hydrophilic
`and lipophilic layers, most effective penetration is obtained
`with drugs having both lipid and hydrophilic properties.
`Highly water soluble drugs penetrate less readily. As an
`
`
`
`
`
`Page 6 of 17
`
`

`

`1566
`
`CHAPTER 89
`
`example highly water soluble steroid phosphate esters pen-
`etrate the cornea poorly. Better penetration is achieved with
`the poorly soluble but more lipophilic steroid alcohol; still
`greater absorption is seen with the steroid acetate form.
`In 1976 Lee and Robinson4 and in 1990, Lee5 presented a
`summary of the factors controlling precorneal pilocarpine
`disposition and pilocarpine bioavailability in the rabbit eye.
`Combining experimental work and computer simulation the
`investigators discussed the mechanisms competing with cor—
`neal absorption of pilocarpine.
`Includedwere solution drain-
`age, drug-induced vasodilation, nonconjunctival loss includ-
`ing uptake by the nictitating membrane, conjunctival
`absorption, induced lacrimation and normal tear turnover.
`Subject to experimental conditions the relative effectiveness
`of the factors involved in precorneal drug removal are drain-
`age : vasodilation > nonconjunctival loss > induced lacri—
`mation = conjunctival absorption > normal tear turnover.
`The authors discuss the implications of the mechanisms of
`precorneal drug loss in the design of ocular drug-delivery
`systems including the effect of instilled drug volume on aque-
`ous humor concentration and the amount of drug available for
`systemic absorption. On an absolute basis a smaller volume
`allows more drug to be absorbed. For a given instilled con-
`centration the opposite is true; however, a smaller volume
`instilled remains more efficient, ie, the fraction of dose ab-
`sorbed is greater. Lang6 discusses the transcorneal route of
`absorption of a drug into the eye as that route most effective in
`bringing a given drug to the anterior portion of the eye.
`This route of absorption is enhanced by the water-lipid gradi-
`ent found in the cornea. As previously mentioned, the cor-
`nea is composed of three general layers:
`the lipid-rich epithe-
`lium, the lipid-poor stroma and the lipid—rich endothelium.
`Differential studies on the relative lipid contents of these three
`layers have shown that the corneal epithelium and the corneal
`endothelium both contain approximately 100 times as much
`lipid as the corneal stroma. This, coupledwith the physiologi-
`cal pH of 7.2 t 0.2 and its effect on ionizable drug molecules
`plays the most significant role in corneal penetration.
`Ophthalmic ointments generally produce greater bioavail-
`ability than the equivalent aqueous solution. Because of the
`greater contact time drug levels are prolonged and total drug
`absorption is increased.
`
`Types of Ophthalmic Products
`
`Administration—The instillation of eyedrops remains one
`of the less precise, yet one of the more accepted means of
`topical drug delivery. The method of administration is cum-
`bersome at best, particularly for the elderly, patients with
`poor vision who have difficulty seeing without eyeglasses and
`patients with other physical handicaps. Perhaps, surpris-
`ingly, the majority of patients become quite adept at routine
`instillation.
`The pharmacist should advise each patient to keep the
`following points in mind to aid in the instillation of eyedrops
`0r ointments:
`
`How to Use Eyedrops
`
`1. Wash hands.
`2. With one hand, gently pull lower eyelid down.
`3.
`If dropper is separate, squeeze rubber bulb once while dropper is in
`bottle to bring liquid into dropper.
`4. Holding dropper above eye, drop medicine inside lower lid while
`looking up; do not touch dropper to eye or fingers.
`5. Release lowerlid. Try to keep eye open and not blink for at least 30
`seconds.
`6.
`If dropper is separate, replace on bottle and tighten cap.
`If dropper is separate, always hold it with tip down.
`0
`0 Never touch dropper to any surface.
`0 Never rinse dropper.
`0 When dropper is at top of bottle, avoid contaminating cap when
`removed.
`ie, when
`0 When dropper is a permanent fixture on the bottle,
`supplied by a pharmaceutical manufacturer to the pharmacist, the same
`rules apply to avoid contamination.
`~
`
`
`
`0 Never use eye drops that have changed color.
`
`
`
`_
`
`
`If you have more than one bottle of the same kind of dmp
`0
`
`only one bottle at a time.
`If you are using more than one kind of drop at the same ti
`0
`
`several minutes before use of other drops.
`
`It may be helpful in use of the medicine to practiCe
`0
`positioning yourself in front of a mirror.
`
`
`0 After instillation of drops, do not close eyes tightly and try
`blink more often than usual, as this removes the medicine from th 11
`on the eye where it will be effective.
`
`93.“?
`
`
`
`
`
`
`How to Use Ophthalmic Ointments
`Wash hands.
`Remove cap from tube.
`With one hand, gently pull lower eyelid down.
`
`4. While looking up, squeeze a small amount of ointment (abou
`
`1/2 in) inside lower lid. Be careful not to touch tip of tube to eye, 'e'
`
`fingers, etc.
`5. Close eye gently and roll eyeball in all directions while eye is c
`Temporary blurring may occur.
`,
`6. The closed eyelid may be rubbed very gently by a finger to dist
`the drug throughout the fornix.
`7. Replace cap on tube.
`
`
`0 Take care to avoid contaminating cap when removed.
`0 When opening ointment tube for the first time, squeeze out.
`
`'
`first 1/4” of ointment and discard as it may be too dry.
`_
`0 Never touch tip of tube to any surface.
`If you have more than one tube of the same ointment, open 0
`0
`one at a time.
`_,
`o
`If you are using more than one kind of ointment at the same ti
`
`wait about 10 minutes before use of another ointment.
`.
`
`0
`To improve flow of ointment, hold tube in hand several minut
`_
`warm before use.
`
`It may be helpful in use of the ointment to practice use by posit
`0
`ing yourself in front of a mirror.
`
`means of administering a drug to the eye.
`
`59 ophthalmic solutions. By definition, all ingredients
`
`completely in solution, uniformity is not a problem and th ,
`
`is little physical interference with vision. The principal disa:
`
`vantage of solutions is the relatively brief contact time b’
`tween the medication and absorbing surfaces. Contact tlm
`
`may be increased to some extent by the inclusion of a viscosi
`
`Inclusions of th
`increasing agent such as methylcellulose.
`sort are permitted by the USP. A Viscosity in the range of 1
`
`to 25 cps is considered optimum for drug retention and visu
`comfort.
`
`
`Ophthalmic Suspensions—Suspensions are dispersio
`
`of finely divided, relatively insoluble drug substances in a
`
`aqueous vehicle containing suitable suspending and disper
`
`ing agents. There are 29 listed in the USP. The vehicle i
`
`among other things, a saturated solution of the drug substanc
`
`Because of a tendency of particles to be retained in the cul—de‘:
`
`sac, the contact time and duration of action of a suspension
`
`probably exceeds that of a solution. The drug is absorbed
`from solution-and the solution concentration is replenished»
`
`from retained particles. Each of these actions is a function
`of particle size, with solubility rate being favored by smaller
`
`size and retention favored by a larger size; thus, optimu
`activity should result from an optimum particle size.
`
`For aqueous suspensions the parameters of intrinsic solubil-
`
`ity and dissolution rate must be considered. The intrinsic
`solubility determines the amount of drug actually in solution
`
`and available for immediate absorption upon instillation of the
`
`dose. As the intrinsic solubility of the drug increases, the
`
`concentration of the drug in the saturated solution surround—
`ing the suspended drug particle also increases. For this rea _
`son, any comparison of different drugs in suspension systems 1
`should include their relative intrinsic solubilities. The ob-
`served differences in their biological activities may be as—
`cribed wholly or in part to the differences in this physical
`parameter. As the drug penetrates the cornea and the initial
`saturated solution becomes depleted, the particles must dis'
`solve to provide a further supply of the drug. The require-
`ment here is that the particles must undergo significant disso-
`
`
`
`
`
`
`
`Page 7 of 17
`
`

`

`its
`
`‘ within the residence time of the dose in the eye if any
`2%: is to be gained from their presence in the dosing
`
`3:: drug whose dissolution rate is rapid, the dissolution
`. irement may present few problems, but for a slowly soluble
`
`Ptaflce the dissolution rate becomes critical.
`If the disso-
`5
`rate is not sufficiently rapid to supply significant addi-
`
`a1 dissolved drug, there is the possibility that the slowly
`
`{able substance in suspension provides no more drug to the
`
`0118 humor than does a more dilute suspension or a
`, ated solution of the substance in a similar vehicle.
`
`«ously, the particle size of the suspended drug affects the
`
`‘ ace area available for dissolution. Particle size also plays
`
`ponant part in the irritation potential of the dosing
`
`tem- This consideration is important, as irritation pro-
`
`c’es excessive tearing and rapid drainage of the instilled
`It has been recommended that particles be less than
`
`m in size to minimize irritation to the eye: ‘- lt‘should be
`
`in mind, however, that in any suspension system the
`
`s of prolonged storage and changes in storage tempera-
`
`e_may'cause the smallest’particles to dissolve and the
`
`“ st particles to become larger.
`In summary, aqueous
`
`nSions should, in general, give a more extended effect
`
`n aqueous solutions.
`"
`
`The pharmacist should be aware of two potential difficulties
`
`‘erent in suspension dosage forms.
`In the first instance
`
`uniformity nearly always requires brisk shaking to
`
`tribute the suspended drug. Adequate shaking is a func-
`
`nt at the same
`.
`.
`‘
`
`d most Importantly, patient compliance.
`1 several minu
`strated that a significant number of patients may not shake
`
`container at all, others may contribute a few trivial shakes.
`,ice use by pos
`e pharmacist should stress the need of vigorous shaking
`
`'enever an ophthalmic suspension is dispensed.
`
`A second and infrequent characteristic of'suspensions is the
`3 most com
`
`enomenon of polymorphism or the ability of a substance‘to
`e USP descr
`
`in several different crystalline forms. A change in crys-
`ingredients
`structure may occur during storage resulting in an increase
`)blem and t
`
`decrease) in crystal size and alteration in the suspension
`principal di
`
`aracteristics causing solubility changes reflected in in-
`ontact time
`
`ased or decreased bioavailability.
`,
`Contact
`The pharmacist should be aware of the procedures used by
`on of a visco
`
`armaceutical manufacturers in the preparation of commer-
`iclusions of
`
`lsterile ophthalmic suspensions and ointments, when called
`
`on to compound such preprations extemporaneously.7
`
`Ophthalmic Ointments—Despite disadvantages, ophthal-
`
`c ointments remain a popular and frequently prescribed
`
`_ Osage form. There are '58 ophthalmic ointments listed in
`ibstances in
`
`e USP. Dosage variability probably is greater than with
`ng and disp
`
`gh probably not with suspensions). Oint—
`The vehicl
`
`-
`instillation.
`
`_ Ointments do offer the advantage of longer contact time and
`
`greater total drug bioavailability, albeit with slower onset and
`
`t1me to peak absorption. The relationship describing the
`
`availability of finely divided solids dispersed in an ointment
`as is a func
`
`base Was given by Higuchi8 where the amount of solid (drug)
`)red by sma
`
`Feleased in unit time is a function of concentration, solubility
`thus, optim
`
`m the ointment base and diffusivity of the drug in the base.
`.0 SDecial precautions must be taken in the preparation of
`(1:12:310 50111
`
`The intfin
`.phthalmic ointments. They are manufactured from steril-
`
`reed ingredients under rigidly aseptic conditions and meet the
`ally in 5011,:
`
`stillation of
`ti quflements ofthe officral sterility tests.‘ Terminal steriliza-
`
`increases, th
`afin ofthe finished ointment intubes is accomphshed occasion—
`
`ltion surrO
`y 93mg a validated dose of gamma radiation.
`If the spe-
`For this r
`C 1ngredients used in the formulation do not lend themselves
`
`13%I‘Outine sterilization techniques, other ingredients that meet
`
`.ties.
`
`es may be
`:0 t5: along with aseptic manufacture, may be employed
`
`1 this phyS
`mPhthalmic ointments must contain a suita

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket